View Author
patient study treatment genotype polymorphism therapy stroke pharmacogenetic antihypertensive statin effect antihypertensive drugs result warfarin diuretic dosing coumarin interaction genotyping event group netherland cyp 2c subject vkorc control number disease trial university hypertension response anticoagulation table index date health allele index antipsychotic month coumarin derivatives association difference pharmacy method analysis variant –effectivenes blood factor utrecht population range cost –effectiveness acenocoumarol covariate value effectiveness anticoagulant carrier fracture research dopamine history atrial fibrillation hip /femur fracture fi rst month blood pressure pharmacogenomic pressure ratio outcome future signi pharmo women incidence genotype-guided vkorc 1 level
10 Most Recent Publications
|
Electrocardiographic characteristics of patients with chronic obstructive pulmonary disease
(Article)
Warnier, M.J. Rutten, F.F.H. Numans, M.E. Kors, J.A. Tan, H.L. Boer, A. de Hoes, A.W. Bruin, M.L. de |
2013-02-01
|
|
The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon
(Letter To Editor)
Verhoef, T.I. Zuurhout, M.J.L. Schie, R.M.F. van Orlewska, E. Meer, F.J.M. van der Cessie, S. le Schalekamp, T. Boer, A. de Maitland-van der Zee, A-H. |
2012-12-01
|
|
Cost-effectiveness of pharmacogenetics in anticoagulation: International differences in healthcare systems and costs
(Article)
Verhoef, T.I. Orlewska, E. Manolopoulos, V.G. Pirmohamed, M. Siebert, U. Stingl, J.C. Wadelius, M. Boer, A. de Maitland-van der Zee, A-H. Schie, R.M.F. van Bayat, S. Daly, A.K. Geitona, M. Haschke-Becher, E. Hughes. D.A. Kamali, F. Levin, L.A. |
2012-09-01
|
|
Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users
(Article)
Verhoef, T.I. Orlewska, E. Visser, L.E. Maitland-van der Zee, A-H. Buikema, M.M. Schalekamp, T. Meer, F.J.M. van der Cessie, S. le Wessels, J.A.M. Schie, R.M.F. van Boer, A. de Teichert, M. |
2012-04-01
|
|
Future of Pharmacogenetics in Cardiovascular Diseases
(In Book)
Schie, R.M.F. van Verhoef, T.I. Maitland-van der Zee, A-H. Boer, A. de Meer, F.J.M. van der Redekop, W.K. Thariani, R. |
2012-01-01
|
|
Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction
(Article)
Peters, B.J.M. Rodin, A.S. Klungel, O.H. Duijn, C.M. van Stricker, B.H.Ch. Slot, R.V. Boer, A. de Maitland-van der Zee, A-H. |
2010-08-01
|
|
Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin
(Article)
Verhoef, T.I. Schalekamp, T. Redekop, W.K. Boer, A. de Maitland-van der Zee, A-H. |
2010-08-01
|
|
A systematic review of cost-effectiveness analyses of pharmacogenetic- guided dosing in treatment with coumarin derivatives
(Article)
Verhoef, T.I. Redekop, W.K. Darba, J. Geitona, M. Hughes. D.A. Siebert, U. Boer, A. de Maitland-van der Zee, A-H. |
2010-07-01
|
|
Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
(Article)
Pouwels, S. Lalmohamed, A. Souverein, P. Cooper, C. Veldt, B.J. Leufkens, H.G.M. Boer, A. de Staa, T. van Vries, F. de |
2010-01-01
|
|
Reasons for non-response in observational pharmacogenetic research
(Article)
Wieren-de Wijer, D.B.M.A. van Maitland-van der Zee, A-H. Klungel, O.H. Boer, A. de Kroon, A.A. Leeuw, P.W. de Schiffers, P. Janssen. R.G.J.H. Psaty, B.M. Duijn, C.M. van Stricker, B.H.Ch. |
2009-11-27
|